Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

NICE technology appraisal guidance [TA333] Published date:

NICE recommends axitinib as a possible treatment for adults with advanced renal cell carcinoma when drugs called tyrosine kinase inhibitors or cytokines have not worked.

What does this mean for me?

If you have advanced renal cell carcinoma and your doctor thinks that axitinib is the right treatment, you should be able to have the treatment on the NHS if treatment with a type of tyrosine kinase inhibitor called sunitinib or a cytokine has not worked. Axitinib should be available on the NHS within 3 months of the guidance being issued.

You may be able to have axitinib treatment on the NHS if you have had a different type of tyrosine kinase inhibitor first (that is, not sunitinib) as long as your doctor gets your written consent to have it and the NHS within your area agrees to provide it.

Get involved